BioArctic Doses First Patient in a Significant Parkinson's Study
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has taken a momentous step in the field of neurodegenerative treatments by dosing the first patient with exidavnemab in the EXIST Phase 2a study aimed at Parkinson's disease patients. This groundbreaking monoclonal antibody is specifically designed to target aggregated forms of ?-synuclein, a protein suspected of contributing to the progression of various neurological disorders, including Parkinson's disease.
Understanding the EXIST Phase 2a Study
The EXIST study, which stands for EXIdavnemab Synucleinopathy Trial, is a carefully structured randomized, double-blind, placebo-controlled trial. It is focused on assessing the safety and tolerability of exidavnemab in patients diagnosed with Parkinson's disease. Conducted in Europe, the study plans to recruit at least 24 participants, who will be divided into two groups of 12. Participants in Cohort 1 will receive either a lower dose of exidavnemab or a placebo, while those in Cohort 2 will be given a higher dose or a placebo. This strategic division aims to provide comprehensive data regarding the drug’s effects.
CEO Gunilla Osswald's Vision
Gunilla Osswald, the CEO of BioArctic, expressed her enthusiasm about the trial, stating, "We are very excited that the first patient with Parkinson's disease has now been dosed in the EXIST Phase 2a study with exidavnemab. This significant milestone marks another step forward in our mission to broaden our research portfolio and to assist families affected by various neurological disorders, enhancing their quality of life." This passion for improving patient outcomes underlines BioArctic’s commitment to innovation in the pharmaceutical industry.
Insights from Phase 1 Studies
The foundational phase of this research was laid with the results from two Phase 1 studies of exidavnemab, which were conducted collaboratively with AbbVie and recently published in The Journal of Clinical Pharmacology. The findings revealed that exidavnemab is generally well-received by patients, showcasing an impressive half-life of approximately 30 days. Such characteristics, along with its high affinity and selectivity for pathological aggregates of ?-synuclein, are critical in ensuring robust binding to targets within the brain, establishing strong support for the objectives of the Phase 2a study.
About Exidavnemab
Exidavnemab is not just a drug candidate; it represents a pivotal advancement in battling neurodegenerative diseases, particularly Parkinson's. This monoclonal antibody is engineered to target and eliminate harmful aggregated forms of alpha-synuclein, including oligomers and protofibrils, that contribute to disease progression. The mission surrounding exidavnemab is to create a disease-modifying treatment that may slow or halt the advancement of Parkinson's disease and related conditions.
BioArctic's Broader Contributions
BioArctic AB has firmly positioned itself as a noteworthy player in the biopharma landscape focused on developing innovative treatments that target neurodegenerative diseases. The company is recognized for its pioneering work with Leqembi, the world’s first drug to demonstrably slow the progress of Alzheimer's disease in its early stages. Collaborating with its partner Eisai, which manages regulatory interactions and global commercialization, BioArctic continues to expand its research portfolio. This includes robust projects targeting both Parkinson's disease and ALS, as well as ongoing initiatives against Alzheimer’s disease.
Contact Information for BioArctic
For additional inquiries regarding this study or overall company information, please reach out to:
Oskar Bosson, Vice President Communications and Investor Relations
Phone: +46 70 410 71 80
Frequently Asked Questions
What is the purpose of the EXIST Phase 2a study?
The EXIST Phase 2a study aims to evaluate the safety and tolerability of exidavnemab in patients with Parkinson's disease.
How many patients will participate in this study?
At least 24 patients are expected to be recruited for the EXIST Phase 2a study.
What does exidavnemab target?
Exidavnemab is designed to target aggregated forms of the protein ?-synuclein, which are implicated in Parkinson's disease progression.
What earlier studies support this trial?
Two Phase 1 studies conducted in collaboration with AbbVie were published recently, highlighting exidavnemab's favorable tolerability and half-life.
How does BioArctic contribute to neurological research?
BioArctic develops innovative treatments for neurodegenerative diseases and has a broad portfolio that includes antibodies against conditions like Alzheimer's and Parkinson's disease.
